Skip to content

Endoscopic Injection Sclerotherapy Versus Endoscopic Band Ligation for Grade I-III Internal Hemorrhoids

Prospective Multicenter Clinical Study of Flexible Endoscopic Treatment for Grade I-III Internal Hemorrhoids

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05089500
Enrollment
984
Registered
2021-10-22
Start date
2021-11-01
Completion date
2026-03-29
Last updated
2026-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemorrhoid, Hemorrhoid Bleeding, Hemorrhoid Pain, Hemorrhoid Prolapse, Hemorrhoids, Hemorrhoids Internal

Keywords

Endoscopic injection sclerotherapy, Endoscopic Band Ligation, Hemorrhoids, Hemorrhoid, Soft Endoscopy

Brief summary

This study is a prospective, multicentre, and randomized-controlled clinical study.The researchers wanted to explore the optimal treatment regimen for soft hemorrhoid within I-Ⅲ degrees by evaluating and comparing the effectiveness, safety and cost effect ratio of sclerosing injection and rubber lap ligation in patients with different internal hemorrhoid scores

Detailed description

Continuous recruitment of symptomatic internal hemorrhoid patients who visited the main center and sub centers was conducted using a stratified block randomization method, with a 1:1 random allocation to the endoscopic injection sclerotherapy group and endoscopic band ligation group for intervention. During the perioperative period, demographic characteristics, intraoperative conditions, postoperative complications and surgery related costs, length of hospital stay were recorded, and HDSS, EQ-5D-5L, EQ-VAS scores were recorded. Changes in scores were recorded during telephone follow-up at 2 weeks, 3 months, and 12 months after surgery, as well as whether the patient's symptoms improved, recurred, and satisfaction was assessed.

Interventions

OTHEREndoscopic injection sclerotherapy

Patients were randomized assigned to the EIS group, preparing disposable endoscopic injections and sclerosing which were routinely administered with 1% polycinol.The transparent cap was fixed at the front end of the endoscope in inverted or orthofield of view.The stiffening agent or foam stiffer added to Meilan was injected with a disposable injection needle at 4-6 points at the oral end near the dentate line. Each point contained 0.2-1ml, and stopped after the hemorrhoid nucleus changed color. If necessary, a transparent cap was pressed to stop the bleeding to distribute the stiffening agent evenly.

Patients were randomized assigned to the EBL group and were to be prepared before surgery.After the socket is mounted at the inner lens end, the socket is obviously tied at 1-2cm hemorrhoids at the mouth above the dentate line, usually 2-4 rings.With mucosal prolapse, pericyclic multiple dislocation ligation can be performed 2-3cm above the obvious prolapse.

Sponsors

Renmin Hospital of Wuhan University
Lead SponsorOTHER
Zhejiang University
CollaboratorOTHER
The First Affiliated Hospital of Nanchang University
CollaboratorOTHER
Wuhan Puren Hospital
CollaboratorOTHER
Yichang Central People's Hospital
CollaboratorOTHER
Fuyang Second People's Hospital
CollaboratorUNKNOWN
Hubei Hospital of Traditional Chinese Medicine
CollaboratorOTHER
Shanxi Provincial Fifth People's Hospital
CollaboratorUNKNOWN
The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture
CollaboratorOTHER
Jingzhou First People's Hospital
CollaboratorUNKNOWN
Chibi People's Hospital
CollaboratorUNKNOWN
Tianyou Hospital Affiliated to Wuhan University of Science and Technology
CollaboratorOTHER
Central Hospital of Xiaogan
CollaboratorOTHER
Xiaogan First People's Hospital
CollaboratorUNKNOWN
The First Affiliated Hospital of Army Medical University (Southwest Hospital)
CollaboratorUNKNOWN
Wuhan University of Science and Technology Affiliated Hanyang Hospital
CollaboratorUNKNOWN

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

1. Age 18 to 75, men and women; 2. Patients with clinical symptoms of degree I-Ⅲ internal hemorrhoids confirmed after medical history collection, clinical examination or colonoscopy; 3. The patient was willing to receive minimally invasive treatment for internal hemorrhoids and sign informed consent by himself or his legal agent.

Exclusion criteria

1. Age \<18 or age\> 75; 2. External hemorrhoids or mixed hemorrhoids; 3. degree Ⅳ internal hemorrhoids 4. Unsymptomatic internal hemorrhoids 5. Internal hemorrhoids were combined with complications such as chimerism, thrombosis, ulceration, or infection; 6. Poor basic conditions can not tolerate endoscopic treatment, such as serious cardiovascular and cerebrovascular diseases, respiratory dysfunction, liver and kidney failure, mental disorders, etc.; 7. There are other serious diseases involving the rectum and anus, such as anal fistula, perianal infection, anal stenosis, inflammatory bowel disease activity period, colorectal tumors, etc.; 8. Patients with severe coagulation dysfunction or long-term oral anticoagulant drugs or antiplatelet aggregation drugs without withdrawal; 9. Women in pregnancy or puerperium; 10. Hardening agent allergy patients, such as polycininol, etc; 11. Previous history of endoscopic treatment of hemorrhoid disease, surgical history or other low rectal and anal surgery history; 12. The patient was unwilling to receive endoscopic treatment for internal hemorrhoids, and himself or his legal agent refused to sign the informed consent form.

Design outcomes

Primary

MeasureTime frameDescription
recurernce rate12 months after surgeryAfter treatment, the recurrence of internal hemorrhoids symptoms

Secondary

MeasureTime frameDescription
Postoperative complications and adverse eventsPostoperative and follow-up periodsPatients from complications and adverse events following intervention (postoperative bleeding, anal distension, pain, urinary retention and others)
early symptom relief rates2 weeks and 3 months after surgeryself-rated improvement postoperative 2 weeks and 3 months
HDSS2 week, 3 month, 12 month after surgeryHemorrhoid Disease Symptom Score, scale 0-20, high score means better
EQ-5D-5L2 week, 3 month, 12 month after surgerythe European Quality of Life 5-Dimensions 5-Levels questionnaire, scale -1 \~ 1, high scores means better outcome
EQ-VAS2 week, 3 month, 12 month after surgerythe European Quality of visual analogue scale, scale 0-100, high value means better
Surgical costsAfter surgeryCost of treatment
Patient satisfaction survey3 months or 12 months after surgeryPatient satisfaction evaluation of the treatment method

Countries

China

Contacts

PRINCIPAL_INVESTIGATORMingkai Chen, M.D

Renmin Hospital of Wuhan University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 16, 2026